002907.SZ
华森制药
SZSE · Healthcare · C 制造业 · CN
CNY 14.31
+0.35%Aug 25, 2026, 07:50 UTC
Huasen Pharmaceutical received a drug re-registration approval notice from the Chongqing Medical Products Administration for its injection of ethylenediamine diaceturate (0.2g, 0.4g), valid until February 20, 2032.
Source:Aug 20, 2026, 10:04 UTC
Huasen Pharmaceutical proposed a cash dividend of 0.35 yuan per 10 shares (tax included) based on total share capital of 418 million shares as of June 30, 2026, with no bonus shares or capital reserve conversion.
Source:Aug 20, 2026, 10:04 UTC
Huasen Pharmaceutical announced its first-half 2026 results: revenue of 414 million yuan, down 6.42% year-on-year; net profit attributable to shareholders of 62.98 million yuan, up 16.74% year-on-year.
Source:Aug 3, 2026, 07:58 UTC
Huasen Pharmaceutical's penehyclidine hydrochloride injection was provisionally selected in the 12th national centralized drug procurement at a provisional winning price of 3.57 yuan per vial, with a procurement period ending December 31, 2029.
Source: